BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review

Stock News

05/13

BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1182859003"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182859003\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182859003?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182859003","market":"other","top_or_hot":-1,"title":"BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review","media":"Stock News","content":"<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Surges Over 7% in Morning Trading as KJ103 Injection Advances to Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1182859003","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182859003","pubTimestamp":1778638527,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","02659":"宝济药业-B","BK1161":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"宝药业-B早盘大涨超7%，KJ103注射液晋级优先审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1,"VXUS":1},"content_text":"BAO PHARMA-B (02659) rose more than 7% in morning trading. As of press time, the stock was up 6.99% to HK$29.4, with a turnover of HK$86.0639 million. On the news front, on May 12, the CDE website indicated that BAO PHARMA's KJ103 injection is proposed to be included in the priority review process. It is intended for desensitization therapy in highly sensitized kidney transplant patients, effectively clearing pre-existing HLA antibodies to prevent hyperacute rejection. According to reports, KJ103 is a first-in-class, low-immunogenicity recombinant immunoglobulin G (IgG) degrading enzyme for the treatment of various immune diseases mediated by pathological IgG antibodies. The product works by specifically cleaving and degrading pathological IgG antibodies in the bloodstream, inhibiting immune response activation, and providing a targeted, rapid new treatment option for antibody-mediated autoimmune diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}